Riociguat (Adempas — Bayer HealthCare) indication: chronic thromboembolic pulmonary hypertension
CADTH
Record ID 32015000180
English
Authors' recommendations:
The Canadian Drug Expert Committee (CDEC) recommends that riociguat be listed for the management of inoperable chronic thromboembolic pulmonary hypertension (CTEPH, World Health Organization [WHO] Group 4) or persistent or recurrent CTEPH after surgical treatment in adult patients (≥ 18 years of age) with WHO Functional Class (FC) II or III pulmonary hypertension (PH), if conditions are met.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/complete/SR0353_complete_Adempas_Jul-21-14.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Hypertension, Pulmonary
- Pyrazoles
- Pyrimidines
- Soluble Guanylyl Cyclase
- Pulmonary Arterial Hypertension
- Enzyme Activators
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.